C. Cordeiro (Coimbra, Portugal), J. Behr (Munich, Germany)
Pentoxifylline and reduced doses of steroids combination in pulmonary sarcoidosis
H. Baradzina, I. Kotovich, A. Tahanovich (Minsk, Belarus)
|  |
The role of oxidative stress and pro-inflamatory cytokines in exogenous toxic alveolites (ETA)
G. Orlova, M. Malishev (Sankt, Petersburg, Russian Federation)
|  |
Oxidative stress in patients with pulmonary sarcoidosis: the role of systemic corticosteroids
A. Koutsokera, Z. Daniil, A. I. Papaioannou, T. Kiropoulos, A. Katsabeki, T. Kerenidi, K. I. Gourgoulianis (Larissa, Greece)
| |
Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD)
A. Boots, M. Drent, A. Bast, G. Haenen (Maastricht, Netherlands)
| |
The dietary antioxidant quercetin reduces markers of oxidative stress and inflammation in sarcoidosis
A. Boots, M. Drent, A. Bast, G. Haenen (Maastricht, Netherlands)
| |
N-acetylcysteine reduces tumor necrosis factor-α release by alveolar macrophages of interstitial lung disease in vitro
Q. Ye, A. Cui, J. Guzman, U. Costabel (Essen, Bochum, Germany)
| |
Does tumor necrosis factor-α (TNFα) protect immune cells from apoptosis in lower airways?
P. Kopinski, J. Soja, A. Szlubowski, M. Plato, B. Balicka, G. Pinis, J. Szczeklik, K. Sladek (Bydgoszcz, Krakow, Poland)
| |
Parameters of antioxidant protection in patients with cryptogenic fibrosing alveolitis
O. P. Baranova, E. K. Dotsenko, L. N. Novikova, D. V. Dzadzua (Saint-Petersburg, Russian Federation)
| |
Vasodilator therapy, exercise tolerance and oxidant stress in IPF patients
O. Gomez, C. Ramos, A. LaPerriere, M. Glassberg, R. Jackson (Miami, FL, United States Of America)
| |
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis
N. Topaloglu, T. Lacin, E. Bas, C. Ataizi, B. Ceyhan (Istanbul, Turkey)
| |
Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF)
C. Rany, J. W. Kim, K. Harris, G. Smaldone (New York, NY, United States Of America)
| |
In vitro effects of vibrating mesh nebulization and radiopharmaceuticals on interferon gamma
K. Harris, L. Morra, A. Shah, G. Smaldone (Stony Brook, NY, United States Of America)
| |
Effect of bosentan in patients with confirmed usual interstitial pneumonia (UIP) on surgical lung biopsy (SLB): subset analysis of the randomised, controlled BUILD 1 trial in IPF
A. G. Nicholson, J. Behr, K. K. Brown, R. M. du Bois, T. E. King, Jr, G. Raghu, K. D. Jones (London, United Kingdom; Munich, Germany; Denver, CO, San Francisco, CA, Seattle, WA, United States Of America)
| |
Effect of curcumin on inflammation in experimental pulmonary fibrosis
M. Ben Brahim, N. Kourda, B. Soltani, L. Charbi, S. Maalej, F. Tritar, S. Ben Khamsa (Tunis, Ariana, Tunisia)
| |
The effect of smoking to oxidative stress on lung tissue of rats with inhaled and intratracheal bleomycin induced pulmonary fibrosis
S. Yosunkaya, K. Uzun, K. Basarali, S. Buyukbas, T. Teke, E. Maden, C. Korkmaz, F. Ozer (Konya, Turkey)
| |
The effect of smoking on blood and lavage fluid IL-4, 6, 10, 12, 13, TNF-α and γ-INF levels of rats with bleomycin induced pulmonary fibrosis
K. Uzun, E. Maden, T. Teke, C. Korkmaz, A. Kiyici, F. Ozer (Konya, Turkey)
| |
Gastroesophageal reflux disease (GERD) in idiopathic pulmonary fibrosis (IPF): a community pulmonary practice experience
S. Bhat, R. Morrison, S. Enjeti (Chattanooga, TN, United States Of America)
| |
Different expression of heme oxygenase-1 in alveolar macrophages in idiopathic interstitial pneumonia
A. Cui, Q. Ye, J. Guzman, U. Costabel (Essen, Bochum, Germany)
| |